Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Genetic Services Laboratory, |
RCV000193088 | SCV000246757 | uncertain significance | not specified | 2015-06-01 | criteria provided, single submitter | clinical testing | |
| Labcorp Genetics |
RCV001360060 | SCV001555955 | uncertain significance | Alpha thalassemia-X-linked intellectual disability syndrome | 2024-03-12 | criteria provided, single submitter | clinical testing | This sequence change replaces asparagine, which is neutral and polar, with serine, which is neutral and polar, at codon 1265 of the ATRX protein (p.Asn1265Ser). This variant is present in population databases (rs371187842, gnomAD 0.001%), including at least one homozygous and/or hemizygous individual. This variant has not been reported in the literature in individuals affected with ATRX-related conditions. ClinVar contains an entry for this variant (Variation ID: 210495). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt ATRX protein function with a negative predictive value of 95%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
| Natera, |
RCV001360060 | SCV002087292 | uncertain significance | Alpha thalassemia-X-linked intellectual disability syndrome | 2020-04-11 | no assertion criteria provided | clinical testing |